AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Study: Panzem safe with prolonged stable disease and clinical benefit.(Brief Article)
2002 JUL 11 - (NewsRx.com & NewsRx.net) -- EntreMed, Inc., (ENMD) a company focused on angiogenesis research and product development, released additional phase I data demonstrating that Panzem is well tolerated and stabilized disease for prolonged periods in patients with refractory metastatic breast cancer.
Panzem provided clinical benefit in several patients. Further, clinical investigators reported that Panzem, a natural metabolite of estrogen in capsule form, did not alter patient hormone levels. The data were presented at the American Society of Clinical Oncology annual meeting in Orlando.
Clinical investigator George Sledge, MD, Ballve-Lantero professor of oncology at Indiana University School of Medicine, commented, "In this phase I study we are working to determine the safety of Panzem in these patients, all heavily treated previously for advanced breast cancer. We are pleased that Panzem appears safe with no maximum tolerated dose identified." Dr. Sledge continued, "We are eager to bring an improved Panzem, ...
- Study: Panzem safe with prolonged stable disease and clinical benefit.
- Newspaper article from: Angiogenesis Weekly July 12, 2002 700+ words
...The results of this Panzem study, particularly the clinical benefits observed by the investigators...were reported among the clinical benefits during or following treatment with Panzem. These clinical benefits restore a higher quality...
- Panzem formulation selected enhances bioavailability.
- Newspaper article from: Blood Weekly October 30, 2003 700+ words
...has selected the final formulations of Panzem, EntreMed's lead drug candidate currently...expects to transition the reformulated Panzem into new clinical trials in early 2004...are designed to increase the amount of Panzem that circulates in the patient's bloodstream...
- EntreMed Selects Panzem(R) Formulation.
- Press release article from: PR Newswire September 30, 2003 700+ words
...has selected the final formulations of Panzem(R), EntreMed's lead drug candidate...expects to transition the reformulated Panzem(R) into new clinical trials in early...are designed to increase the amount of Panzem(R) that circulates in the patient...
- EntreMed's New Panzem(R) Formulations Increase Tumor Inhibition In Preclinical...
- Press release article from: PR Newswire November 20, 2003 700+ words
...demonstrating that its new formulations of Panzem(R) have increased antitumor activity...bioavailability, leading to higher blood levels of Panzem(R) after oral dosing in preclinical...maintained with no evidence of new toxicities. Panzem(R), the Company's lead drug candidate...
- Preclinical data supports Panzem application for osteoporosis.
- Magazine article from: Women's Health Weekly March 27, 2003 700+ words
...published a preclinical study demonstrating Panzem's potential use in preventing and treating...postmenopausal women. In this preclinical study, Panzem compared favorably with other accepted...the March 2003 issue of Endocrinology. Panzem, EntreMed's lead small molecule drug...
- EntreMed Preclinical Data Supports Panzem(TM) Application For Osteoporosis.
- Press release article from: PR Newswire February 24, 2003 700+ words
...published a preclinical study demonstrating Panzem(TM)'s potential use in preventing...postmenopausal women. In this preclinical study, Panzem(TM) compared favorably with other accepted...cgi-bin/prnh/20010620/ENMDLOGO ) Panzem(TM), EntreMed's lead small molecule...
- Preclinical Data Conclude EntreMed's Panzem(R) Inhibits Hypoxia Inducible...
- Press release article from: PR Newswire April 22, 2003 700+ words
...today published preclinical findings that Panzem(R)'s anti-tumor and anti-angiogenesis...inducible factor 1). These data establish Panzem(R) [2-methoxyestradiol (2ME2...commented, "With these data confirming Panzem(R) as a microtubule and HIF inhibitor...
- Entremed AACR Studies Reveal Panzem(R)'s Action and Support Further Clinical...
- Press release article from: PR Newswire July 14, 2003 700+ words
...today announced preclinical data on Panzem(R) (2-methoxyestradiol or 2ME2...s scientists continued development of Panzem(R) and new chemical entities based...research to build on our understanding of Panzem(R)'s mechanisms of actions. With...